Hepatitis C Home > Hepatitis C Treatment

Hepatitis C treatment usually includes the drugs peginterferon and ribavirin. Depending on the genotype, a third drug may be added to the regimen. Peginterferon is given by injection once a week, and ribavirin is a pill taken twice daily. Treatment for hepatitis C is successful in about 50 percent of people with genotype 1 and in about 75 to 80 percent of people with genotype 2.

An Overview of Hepatitis C Treatment

Chronic hepatitis C is a condition that can lead to more and more liver damage over time. However, everyone's situation is a little different. So, before hepatitis C treatment is recommended, your healthcare provider will review the results of your blood work and other tests to determine several things, including:
Then together, you and your healthcare provider can decide what hepatitis C treatment, if any, is best for you.

Current Treatments for Hepatitis C

Previously, hepatitis C treatment usually included a couple of drugs called peginterferon and ribavirin. More recently, the hepatitis C protease inhibitors for genotype 1 became available to be used in combination with peginterferon and ribavirin. The newest hepatitis drug is sofosbuvir (Sovaldi™), which is used in combination with ribavirin for genotypes 2 and 3 or with ribavirin and peginterferon for genotypes 1 and 4. 
Peginterferon (Pegasys® or Peg-Intron®) is given by injection once a week. Ribavirin (Copegus®, Rebetol®) is a pill taken twice daily. Hepatitis C protease inhibitors include boceprevir (Victrelis®), telaprevir (Incivek®), and simeprevir (Olysio™), all of which are taken by mouth with food. Sofosbuvir is taken once daily by mouth, with or without food.
The goal of these hepatitis C treatment medications is to get rid of the hepatitis C virus completely. This is also called "clearing the virus." By clearing the virus, you may be able to bring down the swelling of the liver, stop the scarring and fibrosis, and possibly reverse some of the liver damage. It may also bring down the long-term risk of liver cancer.
Written by/reviewed by:
Last reviewed by: Arthur Schoenstadt, MD
Last updated/reviewed:
List of references (click here):
Other Articles in This eMedTV Presentation

Topics & Medications


Related Channels

eMedTV Links
Copyright © 2006-2020 Clinaero, Inc.

eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.

This site complies with the HONcode standard for trustworthy health information:
verify here.